IOVA Analyst-Style Valuation
1. CURRENT BUSINESS (Melanoma only)
Amtagvi approved Feb 2024. Revenue trajectory:
• Q1 2025: $49M
• Q2 2025: $60M
• Q1 2026: ~$71M (est)
• Q2 2026: $99M (+66% YoY)
• FY2026 guidance: $410-420M
• Gross margin: 56%, improving each quarter
Melanoma TAM:
• ~8,000-10,000 eligible patients/year in US (advanced, post-PD1)
• Average treatment cost: ~$500,000 per patient
• Theoretical max US revenue: ~$4-5B
• Realistic penetration at maturity (5-7 years): 20-25% = $800M-1.2B US alone
• Ex-US potential: EU approval pending, limited currently
Current run rate: $420M annualised. At 56% gross margin = $235M gross profit. Still burning cash on R&D and SG&A. Profitable at EBITDA level possible by 2027.
2. NEAR-TERM REVENUE MODEL (Melanoma only)
Year Revenue Gross Margin Gross Profit
2026 $415M 56% $232M
2027 $560M 60% $336M
2028 $720M 63% $454M
This is melanoma only, assuming continued penetration + EU launch.
At 8x revenue (biotech growth multiple for approved commercial-stage), melanoma alone = $5.8B market cap = ~$9/share (650M shares outstanding).
That's roughly where the stock is NOW at $9.56. Market is pricing in zero NSCLC value.
3. NSCLC SCENARIO ANALYSIS
Assumptions:
• ~250,000 new NSCLC diagnoses/year in US
• ~60% non-squamous (eligible) = 150,000
• ~45% biomarker-enriched (KRAS wt + HER2 wt + smoker) = 67,500 eligible
• Realistic penetration in second-line post-PD1: 10% at launch, 20% at maturity
• Price: $400,000-500,000 per treatment
Scenario Patients Treated Revenue
Conservative (10% penetration, broad label) 8,000 $3.2B
Base (15% biomarker-enriched) 10,000 $4.0B
Bull (25% penetration + frontline) 25,000 $10B+
Realistic base case 2029-2030 (post-approval): $1-2B NSCLC revenue added to $800M+ melanoma = $1.8-2.8B total revenue
4. PIPELINE OPTIONALITY (NOT priced in)
Program Timeline Peak Revenue Potential
NSCLC second-line (broad) 2028 approval $1-3B
NSCLC biomarker-enriched (Positility) 2029-2030 $2-4B
NSCLC frontline (Opulism) 2030+ $3-5B
Colorectal (KRAS wt) 2029+ $1-2B
Sarcoma (2 subtypes) 2028+ $300-500M
Frontline melanoma 2027+ +$300M incremental
Total peak revenue potential (2030-2032): $5-10B
5. FAIR VALUE ESTIMATE
DCF / Comparable approach:
Scenario 2028 Revenue Multiple Market Cap Per Share
Bear (melanoma only, NSCLC fails) $720M 6x $4.3B $6.60
Base (melanoma + NSCLC approval 2028) $1.4B 7x $9.8B $15
Bull (melanoma + NSCLC + colorectal) $2.5B 8x $20B $31
Risk-weighted (60% base, 25% bull, 15% bear):
= (0.60 × $15) + (0.25 × $31) + (0.15 × $6.60)
= $9 + $7.75 + $1 = ~$18 fair value
6. WHAT THE MARKET IS SAYING AT $9.56
The market is currently pricing:
• Melanoma ramp continues ✓
• NSCLC approval probability: ~20-25% (heavily discounted)
• Zero colorectal / pipeline value
• Execution risk on manufacturing at scale
• Interim CEO discount
That's too pessimistic given 90% manufacturing success rate, existing FDA relationship, and 59.1% biomarker ORR data.
Bottom Line
$9.56 = melanoma-only valuation. Every dollar of NSCLC success is free upside from here. A $15-18 fair value is defensible on a risk-weighted basis if you believe the SBLA gets filed in 2027 and FDA engages constructively.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.
